Wealth Enhancement Advisory Services
ATYR

Wealth Enhancement Advisory Services’s aTyr Pharma ATYR Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.9K Buy
43,948
+28,370
+182% +$18.5K ﹤0.01% 4013
2026
Q1 		$13.2K Buy
+15,578
New +$13.2K ﹤0.01% 3539

Other funds holding ATYR

CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
TCOT
Trust Company of Toledo Holland, Ohio $1.2B AUM 33.38% 1-Year Est. Return
AFC
Ares Financial Consulting Calabasas, California $139M AUM
VR
Vision Retirement Ridgewood, New Jersey $414M AUM
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Wealth Enhancement Advisory Services's ATYR Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its aTyr Pharma (ATYR) stake by 182% in Q2 2026, buying an estimated $18.5K and bringing the position to 43,948 shares worth $23.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4013.

Wealth Enhancement Advisory Services first reported a position in ATYR in Q1 2026 and has held it in 2 quarters since. 11 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

  • Wealth Enhancement Advisory Services held 43,948 shares of aTyr Pharma worth $23.9K as of Q2 2026.
  • Wealth Enhancement Advisory Services bought 28,370 aTyr Pharma shares in Q2 2026, an estimated $18.5K.
  • aTyr Pharma made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #4013 holding.
  • Wealth Enhancement Advisory Services first reported a position in aTyr Pharma in Q1 2026 and has held it in 2 quarters since.
  • 11 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.